DiaMedica Therapeutics (DMAC) Competitors

DiaMedica Therapeutics (NASDAQ:DMAC) and Arcus Biosciences (NYSE:RCUS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Which has more volatility & risk, DMAC or RCUS?

DiaMedica Therapeutics has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500.

Do institutionals & insiders hold more shares of DMAC or RCUS?

10.1% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 7.3% of DiaMedica Therapeutics shares are owned by company insiders. Comparatively, 9.6% of Arcus Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Is DMAC or RCUS more profitable?

DiaMedica Therapeutics has a net margin of 0.00% compared to Arcus Biosciences' net margin of -109.56%. Arcus Biosciences' return on equity of -55.96% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-78.99%	-69.94%
Arcus Biosciences	-109.56%	-55.96%	-25.73%

Which has preferable valuation and earnings, DMAC or RCUS?

DiaMedica Therapeutics has higher earnings, but lower revenue than Arcus Biosciences. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$24.44M	-$0.69	-8.86
Arcus Biosciences	$258M	4.34	-$283M	-$3.17	-3.32

Do analysts prefer DMAC or RCUS?

DiaMedica Therapeutics presently has a consensus target price of $12.33, suggesting a potential upside of 101.85%. Arcus Biosciences has a consensus target price of $21.14, suggesting a potential upside of 101.19%. Given DiaMedica Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe DiaMedica Therapeutics is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Arcus Biosciences	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

Does the media favor DMAC or RCUS?

In the previous week, DiaMedica Therapeutics had 1 more articles in the media than Arcus Biosciences. MarketBeat recorded 3 mentions for DiaMedica Therapeutics and 2 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 1.02 beat DiaMedica Therapeutics' score of 0.32 indicating that Arcus Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DiaMedica Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcus Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Arcus Biosciences beats DiaMedica Therapeutics on 8 of the 15 factors compared between the two stocks.